Transaction · 0001229055-26-000002

PIERCE FREDERICK II

PIERCE FREDERICK II, CEO, reported a transaction classified as grant at Decoy Therapeutics Inc. involving 33455.000000 shares for an estimated $0.00. Reported holdings after the transaction were 34844.000000 shares. A 10b5-1 reference was not detected in the stored filing text.

grantSEC transaction code ACEO
DCOYDecoy Therapeutics Inc.
Filing timeSep 02
Trade dateAug 31, 2026
Filing · SECView on SEC
InsiderProfile

Price performance since filing

Close on the filing date, the pre-filing context, and the forward return at standard windows
Price at filing
—
Pre-filing
1mo ago1w ago1d ago
Returns since
7d30d90d180d1y

DCOY price since this filing

30 days of pre-filing context and vertical markers at the filing date plus 7d / 30d / 90d / 180d / 1y afterwards
DCOY since 2026-09-02Filed yesterday · 1 day of post-filing data
Loading…
Filing datePost-filing windows (7d, 30d, 90d, 180d, 1y)30 days of pre-filing context

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
grant
Code A
Identifier
0001229055-26-000002
Common Stock
Transaction date
Aug 31, 2026
Filed Sep 02, 2026, 09:50 PM · 2d delay
Shares
33.4k sh
$0 per share
Estimated value
$0
Computed from shares × price
Holdings after
34.8k sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $10.0MLarge $100M
Direct Ownership Large Holdings Increase
-12score
Filing-only score

-12

Compact filing score computed from stored Form 4 facts. Version v1.

Mixed or weak signal

This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

Chief Executive Officer

Officer YesDirector No10% NoOther No
Footnotes & amended
  1. F1

    Restricted stock granted under the Decoy Therapeutics Inc. 2026 Equity Incentive Plan. 25 percent of the restricted stock vested immediately, and the remainder will vest in approximately equal monthly…

  2. F2

    Shares beneficially owned following the transaction have been adjusted to reflect the reverse stock split effective on March 6, 2026.

Original filing · 0001229055-26-000002
Related transactions

0 other filings

Same reporting owner
Recent company activity

0 recent txs

DCOY